Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$114.51

6.205 (5.73%)

, INTC

Intel

$45.30

-0.21 (-0.46%)

09:55
01/26/18
01/26
09:55
01/26/18
09:55

Early notable gainers among liquid option names on January 26th

Notable gainers among liquid option names this morning include AbbVie (ABBV) $117.59 +9.22, Intel (INTC) $48.71 +3.41, Arthur J. Gallagher (AJG) $69.45 +3.80, Gilead (GILD) $83.96 +2.77, and Biogen (BIIB) $365.10 +10.98.

ABBV

AbbVie

$114.51

6.205 (5.73%)

INTC

Intel

$45.30

-0.21 (-0.46%)

AJG

Arthur J. Gallagher

$68.65

2.995 (4.56%)

GILD

Gilead

$81.19

-0.11 (-0.14%)

BIIB

Biogen

$353.74

7.24 (2.09%)

  • 26

    Jan

  • 06

    Feb

  • 12

    Feb

  • 16

    Feb

  • 08

    Mar

  • 30

    May

ABBV AbbVie
$114.51

6.205 (5.73%)

01/04/18
JEFF
01/04/18
NO CHANGE
Target $120
JEFF
Buy
Jefferies calls AbbVie top pick in Pharma, ups target to $120
Jefferies analyst Jeffrey Holford raised his price target for AbbVie to $120 from $115 and says the stock is his top pick in U.S. Large Cap Pharma. Positive estimate revisions tied to tax reform, the Mavyret launch and share repurchases put the company "in a strong position" to beat and raise through 2018, Holford tells investors in a research note. He believes the company's 2018 guidance is likely too conservative.
01/02/18
PIPR
01/02/18
NO CHANGE
PIPR
Overweight
AbbVie joining peers with typical January price hikes, says Piper Jaffray
Piper Jaffray analyst Richard Purkiss noted that AbbVie (ABBV) took early-January price increases, highlighting that Humira saw a 9.7% increase that is similar in both timing and magnitude to last year's increase and once again "exactly" matches Amgen's (AMGN) Enbrel. In a note of his own earlier this morning titled "'Tis the Season; Price Increases Continue Like Clockwork for Many Biotech Drugs," Piper Jaffray analyst Christopher Raymond highlighted that Amgen and Biogen (BIIB) also increased prices on a number of important franchise products effective January 1, 2018. Purkiss maintains his Overweight rating on AbbVie shares.
01/02/18
RBCM
01/02/18
DOWNGRADE
RBCM
Sector Perform
Enanta downgraded to Sector Perform at RBC Capital after 'considerable run'
As reported earlier, RBC Capital analyst Brian Abrahams downgraded Enanta (ENTA) to Sector Perform from Outperform, saying his positive near-term thesis on Mavyret has now played out and the potential for long-term royalties from AbbVie (ABBV) are "baked into the stock". The analyst believes that the trajectory of the treatment is now better appreciated" by the Street, adding the stock is more likely to trade in line in the immediate term given the "limited patient data for the NASH/PBC and RSV programs in 2018".
12/29/17
PIPR
12/29/17
NO CHANGE
PIPR
Biotech fund outflows continue, says Piper Jaffray
For the weekly period ending Wednesday, December 27, healthcare/biotech funds saw $338M in net outflows, representing a 0.58% decrease in assets, Piper Jaffray analyst Christopher Raymond tells investors in a research note. This marks the seventh straight negative week and the eleventh week of outflows in the past 12 weeks, the analyst points out in a research note titled "Ending 2017 on a Down Note: Biotech Outflows Continue."
INTC Intel
$45.30

-0.21 (-0.46%)

01/26/18
MKMP
01/26/18
NO CHANGE
Target $55
MKMP
Buy
Intel price target raised to $55 from $50 at MKM Partners
MKM Partners analyst Ruben Roy raised his price target on Intel to $55 and kept his Buy rating after Q4 earnings. Roy says the company continues to highlight the data-centric portion of its business as it diversifies away from the PC market, which drive Intel to faster longer-term revenue growth at stronger profitability margins. The analyst expects the multiples to follow, noting that the current valuation appears attractive while raising his FY18 EPS view to $3.55 from $3.25.
01/26/18
BARD
01/26/18
NO CHANGE
Target $60
BARD
Outperform
Intel price target raised to $60, added as top idea at Baird
Intel analyst Tristan Gerra raised his price target on Intel to $60 from $50 and added it as a top idea following the company's better than expected Q4 results. The analyst cited its continued revenue growth and operating margins profile while redistributing its cash. He said some of the upcoming catalysts include AI, 3D NAND, 5G modems, and FGPA's in data centers. Gerra reiterated his Outperform rating on Intel shares.
01/26/18
STFL
01/26/18
NO CHANGE
STFL
Intel demand comments have positve read for Micron, Smart Global, says Stifel
Stifel analyst Kevin Cassidy said the strong demand reported by Intel (INTC), particularly in data center and NAND Flash, are positive for Micron (MU) and Smart Global (SGH). Additionally, customers buying high performance processors benefits interconnect companies such as Mellanox (MLNX), said Cassidy. Intel management also noted strength in the commercial gaming business, which could benefit Nvidia (NVDA) and AMD (AMD), the analyst added.
01/26/18
NEED
01/26/18
NO CHANGE
Target $50
NEED
Buy
Intel price target raised to $50 from $45 at Needham
Needham analyst N. Quinn Bolton raised his price target on Intel to $50 and kept his Buy rating after a Q4 earnings beat and Q1 outlook. Bolton notes that Data Center Group revenue topped expectations for the 2nd straight quarter on strength in Cloud and Enterprise amid the company transition to a data-centric business. The analyst also notes "major" benefits from the U.S. tax changes lowering its effective rate to 14% from 22%-23%.
AJG Arthur J. Gallagher
$68.65

2.995 (4.56%)

01/26/18
RHCO
01/26/18
NO CHANGE
Target $75
RHCO
Buy
Arthur J. Gallagher price target raised to $75 from $70 at SunTrust
SunTrust analyst Mark Hughes raised his price target on Arthur J. Gallagher to $75 and kept his Buy rating after a Q4 earnings beat, citing "slightly faster Brokerage organic growth" as well as positive momentum in pricing and exposures in its core P&C Brokerage business. Hughes adds that the company's valuation is "attractive".
12/13/17
RHCO
12/13/17
NO CHANGE
Target $70
RHCO
Buy
Arthur J. Gallagher has positive growth prospects, says SunTrust
SunTrust analyst Mark Hughes kept his Buy rating and a $70 price target on Arthur J. Gallagher (AJG) after the company's analyst day. Hughes says the management was upbeat on the prospects for property & casualty rates experiencing 20-25% increase in policy renewals, as well as brokerage organic growth, to improve next year. The analyst notes that commentary on the Wholesale segment was particularly positive, which could also benefit James River (JRVR) and Kinsale (KNSL).
10/04/17
DBAB
10/04/17
DOWNGRADE
Target $64
DBAB
Hold
Arthur J. Gallagher downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Joshua Shanker downgraded Arthur J. Gallagher (AJG) to Hold with an unchanged price target of $64 citing valuation following the recent share rally. Recent appreciation of the insurance brokerage stocks has not come with an increase in earnings outlooks, Shanker tells investors in a research note. The analyst this morning also downgraded Marsh & McLennan (MMC).
05/02/17
05/02/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AMD (AMD) downgraded to Underperform from Neutral at Macquarie with analyst Srini Pajjuri telling investors PC progress was disappointing versus high expectations and margin expansion will be difficult. 2. CNA Financial (CNA) downgraded to Hold from Buy at Deutsche Bank with analyst Joshua Shanker citing valuation with the stock up 56% over the past 12 months. The analyst raised his price target for the shares to $46 from $45 following CNA's first quarter results. 3. Arthur J. Gallagher (AJG) downgraded to Market Perform on valuation at Raymond James with analyst Gregory Peters citing valuation. 4. Ocwen (OCN) downgraded to Neutral on valuation at Compass Point with analyst Fred Small citing the over 40% jump in shares following the announcement of a strategic deal with New Residential (NRZ) on Monday. The analyst maintained a $3.50 price target on Ocwen shares and recommends moving to the sidelines until viability into long-term earnings power emerges. 5. Cerner (CERN) downgraded to Neutral from Buy at Hilliard Lyons with analyst Stephen Turner citing price appreciation and raised its price target to $68. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
GILD Gilead
$81.19

-0.11 (-0.14%)

01/22/18
JEFF
01/22/18
NO CHANGE
Target $125
JEFF
Buy
Celgene, Juno deal 'smart' if more than JCAR017 plays out, says Jefferies
Following the announced acquisition of Juno Therapeutics (JUNO) by Celgene (CELG), Jefferies analyst Michael Yee notes that in the short term, the Street will debate whether pivotal Juno data coming will look better than Kite's (GILD) Yescarta and whether JCAR17 is truly differentiated. Longer-term, the analyst believes this is a deal hinged on Celgene's confidence in going "all in" on cell therapy over the next 5-10 years. Like Gilead/Kite, this will be a "smart deal" if more than just JCAR17 plays out, he contends, adding that he thinks it will over next few years. Yee reiterates a Buy rating and $125 price target on Celgene's shares.
01/16/18
SBSH
01/16/18
NO CHANGE
SBSH
Buy
Juno could be worth $110 per share in takeover, says Citi
After the Wall Street Journal reported tonight that Celgene (CELG) is in talks to acquire Juno Therapeutics (JUNO), Citi analyst Robyn Karnauskas says her analysis indicates Juno could be worth $110 per share in a takeover. The stock in after-hours trading jumped 43%, or $19.50, to $65.10. The analyst, however, points that Kite Pharma had more data at the time of acquisition and was acquired by Gilead Sciences (GILD) for an aggregate price of $11.9B. Karnauskas also notes that Celgene already downs 25% of June's revenues.
01/16/18
WELS
01/16/18
UPGRADE
Target $96
WELS
Outperform
Gilead upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Jim Birchenough upgraded Gilead Sciences to Outperform and raised his price target for the shares to $96 from $84. Following management's update last week at a conference, the analyst expects more stable hepatitis C virus trends in 2018, "trough earnings" in 2019, and multiple expansion on growth beyond 2019.
01/26/18
JEFF
01/26/18
UPGRADE
Target $95
JEFF
Buy
Gilead upgraded to Buy from Hold at Jefferies
Jefferies analyst Michael Yee upgraded Gilead Sciences to Buy and raised his price target for the shares to $95 from $87. The drugmaker closed yesterday down 11c to $81.19. Gilead "has had it tough since 2015," but he worst is "generally moving behind them," Yee tells investors in a research note. The analyst sees consensus earnings re-growing in 2020 and beyond and three years of declining. He wants to own the stock coming out of the decline and back into the recovery period. Gilead's upcoming 2018 guidance will likely be low for its hepatitis C virus business, and this should not be surprising, Yee contends. At around $80, the analyst thinks the stock's risk/reward "looks good" with upside to $90-$100 if the business stabilizes and the new pipeline plays out to 2019 and beyond.
BIIB Biogen
$353.74

7.24 (2.09%)

01/26/18
HCWC
01/26/18
NO CHANGE
Target $363
HCWC
Buy
Biogen price target raised to $363 from $340 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein raised his price target for Biogen to $363 and reiterates a Buy rating on the shares following yesterday's Q4 results.
01/26/18
RBCM
01/26/18
NO CHANGE
Target $347
RBCM
Sector Perform
Biogen price target raised to $347 from $321 at RBC Capital
RBC Capital analyst Brian Abrahams raised his price target on Biogen to $347 and kept his Sector Perform rating after Q4 earnings. The analyst says Biogen is a "safe" large cap for 2018 based on its latest stronger-than-expected ex-U.S. Spinraza growth and good MS resilience, but believes the company needs to diversify revenues in the long-term, adding that risk-reward at current levels is balanced.
01/26/18
RHCO
01/26/18
NO CHANGE
Target $392
RHCO
Buy
Biogen price target raised to $392 from $354 at SunTrust
SunTrust analyst Yatin Suneja raised his price target on Biogen to $392 and kept his Buy rating after above-consensus Q4 sales driven by solid performance across business units. Suneja says Sprinza, Biosimilars, and the anti-CD20 franchise will continue to deliver growth to the overall business ahead of the key value inflection Alzheimer's data in late 2019.
01/26/18
DBAB
01/26/18
NO CHANGE
Target $373
DBAB
Buy
Biogen price target raised to $373 from $358 at Deutsche Bank
Deutsche Bank analyst Andrew Peters raised his price target for Biogen to $373 saying the multiple sclerosis franchise continues to show resiliency. While yesterday's Q4 results and initial 2018 financial guidance suggest continued resilience of the core MS franchise and further strength of the Spinraza launch, investor focus for the remainder of 2018 will be on potential capital allocation decisions, Peters tells investors in a post-earnings research note. The analyst views the quarter as a "good start to the year" and reiterates a Buy rating on Biogen.

TODAY'S FREE FLY STORIES

PRO

Pros Holdings

$35.39

-1.91 (-5.12%)

20:39
08/15/18
08/15
20:39
08/15/18
20:39
Syndicate
Pros Holdings 3.8M share Secondary priced at $34.00 »

It appears selling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 21

    Aug

  • 06

    Sep

  • 07

    Sep

  • 16

    Aug

IIN

IntriCon

$63.85

-4.9 (-7.13%)

20:34
08/15/18
08/15
20:34
08/15/18
20:34
Syndicate
IntriCon 1.5M share Secondary priced at $55.00 »

Stifel acted as sole book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 16

    Aug

ADUS

Addus HomeCare

$59.35

-3.1 (-4.96%)

20:33
08/15/18
08/15
20:33
08/15/18
20:33
Syndicate
Addus HomeCare 2.1M share Secondary priced at $59.00 »

Jefferies, RBC Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

LABL

Multi-Color

$63.90

-1 (-1.54%)

20:32
08/15/18
08/15
20:32
08/15/18
20:32
Downgrade
Multi-Color rating change  »

Multi-Color downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$90.24

-0.565 (-0.62%)

, JCP

J.C. Penney

$2.40

-0.24 (-9.09%)

20:25
08/15/18
08/15
20:25
08/15/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

WMT

Walmart

$90.24

-0.565 (-0.62%)

JCP

J.C. Penney

$2.40

-0.24 (-9.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 16

    Aug

WUBA

58.com

$58.59

-3.27 (-5.29%)

19:09
08/15/18
08/15
19:09
08/15/18
19:09
Hot Stocks
Breaking Hot Stocks news story on 58.com »

58.com sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 10

    Sep

WUBA

58.com

$58.59

-3.27 (-5.29%)

19:08
08/15/18
08/15
19:08
08/15/18
19:08
Earnings
58.com reports Q2 adjusted earnings per ADS 82c, consensus 68c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 10

    Sep

WAIR

Wesco Aircraft

$13.65

-0.3 (-2.15%)

19:07
08/15/18
08/15
19:07
08/15/18
19:07
Initiation
Wesco Aircraft initiated  »

Wesco Aircraft initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGI

Triumph Group

$21.10

-0.9 (-4.09%)

19:07
08/15/18
08/15
19:07
08/15/18
19:07
Initiation
Triumph Group initiated  »

Triumph Group initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HXL

Hexcel

$68.40

-1.13 (-1.63%)

19:06
08/15/18
08/15
19:06
08/15/18
19:06
Initiation
Hexcel initiated  »

Hexcel initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

ERJ

Embraer

$18.64

-0.495 (-2.59%)

19:05
08/15/18
08/15
19:05
08/15/18
19:05
Initiation
Embraer initiated  »

Embraer initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CW

Curtiss-Wright

$130.92

-2.42 (-1.81%)

19:04
08/15/18
08/15
19:04
08/15/18
19:04
Initiation
Curtiss-Wright initiated  »

Curtiss-Wright initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLL

L3 Technologies

$208.08

-1.73 (-0.82%)

19:03
08/15/18
08/15
19:03
08/15/18
19:03
Initiation
L3 Technologies initiated  »

L3 Technologies initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$192.29

-1.33 (-0.69%)

19:03
08/15/18
08/15
19:03
08/15/18
19:03
Initiation
General Dynamics initiated  »

General Dynamics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDRBF

Bombardier

$0.00

(0.00%)

19:02
08/15/18
08/15
19:02
08/15/18
19:02
Initiation
Bombardier initiated  »

Bombardier initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEI

Heico

$76.50

-1.81 (-2.31%)

19:00
08/15/18
08/15
19:00
08/15/18
19:00
Initiation
Heico initiated  »

Heico initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 13

    Sep

  • 06

    Nov

HRS

Harris

$162.73

-2.15 (-1.30%)

18:59
08/15/18
08/15
18:59
08/15/18
18:59
Initiation
Harris initiated  »

Harris initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$291.52

-2.35 (-0.80%)

18:59
08/15/18
08/15
18:59
08/15/18
18:59
Initiation
Northrop Grumman initiated  »

Northrop Grumman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNC

PNC Financial

$142.03

-0.7 (-0.49%)

, WFC

Wells Fargo

$57.99

-0.08 (-0.14%)

18:57
08/15/18
08/15
18:57
08/15/18
18:57
Periodicals
PNC faces subpoenas over low-income housing tax credits, Bloomberg says »

PNC Financial (PNC) has…

PNC

PNC Financial

$142.03

-0.7 (-0.49%)

WFC

Wells Fargo

$57.99

-0.08 (-0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Oct

  • 12

    Apr

  • 13

    Jul

  • 15

    Oct

UTX

United Technologies

$131.75

-0.65 (-0.49%)

18:57
08/15/18
08/15
18:57
08/15/18
18:57
Initiation
United Technologies initiated  »

United Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

B

Barnes Group

$65.59

-0.26 (-0.39%)

18:56
08/15/18
08/15
18:56
08/15/18
18:56
Initiation
Barnes Group initiated  »

Barnes Group initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPR

Spirit AeroSystems

$84.51

-1.6 (-1.86%)

18:55
08/15/18
08/15
18:55
08/15/18
18:55
Initiation
Spirit AeroSystems initiated  »

Spirit AeroSystems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TDG

TransDigm

$351.43

-5.195 (-1.46%)

18:54
08/15/18
08/15
18:54
08/15/18
18:54
Initiation
TransDigm initiated  »

TransDigm initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HII

Huntington Ingalls

$240.82

-2.5 (-1.03%)

18:54
08/15/18
08/15
18:54
08/15/18
18:54
Initiation
Huntington Ingalls initiated  »

Huntington Ingalls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTN

Raytheon

$194.92

-2.66 (-1.35%)

18:53
08/15/18
08/15
18:53
08/15/18
18:53
Initiation
Raytheon initiated  »

Raytheon initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.